Literature DB >> 33669403

Apoptosis of Hepatocytes: Relevance for HIV-Infected Patients under Treatment.

Aleksandra Gruevska1,2, Ángela B Moragrega1,2, Andrea Cossarizza3,4, Juan V Esplugues1,2,5, Ana Blas-García2,5,6, Nadezda Apostolova1,2,5.   

Abstract

Due to medical advances over the past few decades, human immunodeficiency virus (HIV) infection, once a devastatingly mortal pandemic, has become a manageable chronic condition. However, available antiretroviral treatments (cART) cannot fully restore immune health and, consequently, a number of inflammation-associated and/or immunodeficiency complications have manifested themselves in treated HIV-infected patients. Among these chronic, non-AIDS (acquired immune deficiency syndrome)-related conditions, liver disease is one of the deadliest, proving to be fatal for 15-17% of these individuals. Aside from the presence of liver-related comorbidities, including metabolic disturbances and co-infections, HIV itself and the adverse effects of cART are the main factors that contribute to hepatic cell injury, inflammation, and fibrosis. Among the molecular mechanisms that are activated in the liver during HIV infection, apoptotic cell death of hepatocytes stands out as a key pathogenic player. In this review, we will discuss the evidence and potential mechanisms involved in the apoptosis of hepatocytes induced by HIV, HIV-encoded proteins, or cART. Some antiretroviral drugs, especially the older generation, can induce apoptosis of hepatic cells, which occurs through a variety of mechanisms, such as mitochondrial dysfunction, increased production of reactive oxygen species (ROS), and induction of endoplasmic reticulum (ER) stress and unfolded protein response (UPR), all of which ultimately lead to caspase activation and cell death.

Entities:  

Keywords:  HIV; antiretroviral drugs; apoptosis; hepatic cell death; liver; toxicity

Year:  2021        PMID: 33669403     DOI: 10.3390/cells10020410

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  2 in total

Review 1.  Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients - a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown.

Authors:  Simona Alexandra Iacob; Diana Gabriela Iacob
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-09       Impact factor: 5.555

2.  Improvement of liver metabolic activity in people with advanced HIV after antiretroviral therapy initiation.

Authors:  Reema Patel; Maura M Manion; Elizabeth Laidlaw; Paul Wakim; Zeping Wang; Megan Anderson; Frances Galindo; Adam Rupert; Andrea Lisco; Theo Heller; Irini Sereti; Dima A Hammoud
Journal:  AIDS       Date:  2022-08-03       Impact factor: 4.632

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.